Differential Regulation of Mesolimbic α3 /α6β2 and α4β2 Nicotinic Acetylcholine Receptor Sites and Function after Long-Term Oral Nicotine to Monkeys
- 1 July 2006
- journal article
- research article
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 318 (1) , 381-388
- https://doi.org/10.1124/jpet.106.104414
Abstract
Because the mesolimbic dopamine system plays a critical role in nicotine addiction/reinforcement and because nicotinic receptors regulate dopamine release, we initiated a study to evaluate the long-term effects of nicotine (>6 months at the final dose) on nicotinic acetylcholine receptor (nAChR) sites and function in the nucleus accumbens of nonhuman primates. Nicotine was given in the drinking water as this mode of administration is long-term but intermittent, thus resembling smoking in this aspect. We determined the effects of nicotine treatment on function and binding of the α3/α6β2* and α4β2* nAChRs subtypes in nucleus accumbens, a region directly implicated in the addictive effects of nicotine. To evaluate function, we measured nicotine and K+-evoked [3H]dopamine release from nucleus accumbens synaptosomes. Changes in α4β2* and α3/α6β2* nAChRs were measured using 125I-epibatidine, [125I]A85380 [5-[125I]iodo-3(2(S)-azetidinylmethoxy) pyridine] and 125I-α-conotoxin MII autoradiography. Chronic nicotine treatment, which led to plasma nicotine levels in the range of smokers, significantly increased nucleus accumbens α4β2* nAChR sites and function compared with control. By contrast, this treatment did not significantly change α3/α6β2* nAChR sites or evoked dopamine release in this region compared with control. Thus, these data are distinct from previous results in striatum in which the same nicotine treatment paradigm decreased striatal α3/α6β2* nAChR sites and function. The finding that long-term nicotine treatment selectively modulates α4β2* and not α3/α6β2* nAChR expression in primate nucleus accumbens is consistent with the results of studies in nicotinic receptor mutant mice implicating the α4β2* nAChR subtype in nicotine-mediated addiction.This publication has 39 references indexed in Scilit:
- Nicotine Acts as a Pharmacological Chaperone to Up-Regulate Human α4β2 Acetylcholine ReceptorsMolecular Pharmacology, 2005
- Metabolism and Disposition Kinetics of NicotinePharmacological Reviews, 2005
- Comparison of the effects of nicotine and epibatidine on the striatal extracellular dopamineEuropean Journal of Pharmacology, 2004
- Chronic nicotine administration does not increase nicotinic receptors labeled by [125I]epibatidine in adrenal gland, superior cervical ganglia, pineal or retinaJournal of Neurochemistry, 2003
- Nicotine addiction: the possible role of functional upregulationTrends in Pharmacological Sciences, 2002
- Declines in Different β2* Nicotinic Receptor Populations in Monkey Striatum after Nigrostriatal DamageThe Journal of Pharmacology and Experimental Therapeutics, 2002
- Molecular and Physiological Diversity of Nicotinic Acetylcholine Receptors in the Midbrain Dopaminergic NucleiJournal of Neuroscience, 2001
- Self-administered nicotine activates the mesolimbic dopamine system through the ventral tegmental areaBrain Research, 1994
- Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats.Proceedings of the National Academy of Sciences, 1988
- Evidence that Tobacco Smoking Increases the Density of (−)‐[3H]Nicotine Binding Sites in Human BrainJournal of Neurochemistry, 1988